ABCL — AbCellera Biologics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1703057 ·
Last close
$5.29
Market Cap
$1.62B
52W High
$5.63
52W Low
$3.22
ADV30
8,498,076
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 8,315,000 | — | -53,180,000 | -43,165,000 | 1,307,112,000 | 77,063,000 | 369,029,000 |
| Dec 2025 | 44,853,000 | — | -25,266,000 | -8,945,000 | 1,356,950,000 | 128,513,000 | 390,046,000 |
| Sep 2025 | 8,955,000 | — | -73,549,000 | -57,119,000 | 1,355,992,000 | 83,159,000 | 391,954,000 |
| Jun 2025 | 17,084,000 | — | -45,893,000 | -34,727,000 | 1,402,061,000 | 92,437,000 | 394,985,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-131,295,000
Investing CF
$87,750,000
Financing CF
$14,082,000
CapEx
$-42,772,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.63
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-29,482,000
Inventory
$6,336,000
Receivables
$153,400,000
ST Investments
$405,313,000
EBIT TTM
$-203,215,000
Pretax Income TTM
$-177,595,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$79,208,000
EBITDA
$-188,284,000
Free Cash Flow
$-105,397,248
Enterprise Value
$1,217,529,088
Total Cash
$504,732,000
Total Debt
$134,308,992
Shares Out
305,375,393
Trailing EPS
$-0.48
Book Value
$3.09
ROE
-14.7%
ROA
-10.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 75,128,000 | -203,213,000 | -146,412,000 | 1,356,950,000 | 390,046,000 | — | -131,295,000 |
| Dec 2024 | 28,833,000 | -301,146,000 | -162,857,000 | 1,360,553,000 | 304,469,000 | — | -108,556,000 |
| Dec 2023 | 38,025,000 | -223,052,000 | -146,398,000 | 1,488,094,000 | 335,776,000 | — | -43,877,000 |
| Dec 2022 | 485,424,000 | 227,065,000 | 158,519,000 | 1,540,907,000 | 307,630,000 | — | 277,360,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$107,890,000
NetIncome TTM
$-24,483,000
OpCashFlow TTM
$0
Assets (Latest)
$1,360,553,000
Forward EPS
$-0.72
Max Pain — expiry 2026-06-18
max pain strike: $4.00 · spot: $5.29 · call oi: 12,055 · put oi: 2,658
Expected Move to 2026-06-18:
±$1.02
(19.38%) —
implied range
$4.26 –
$6.31
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NUVB | Nuvation Bio Inc. | $1.63B | $4.69 | — |
| DMRA | Damora Therapeutics, Inc. | $1.59B | $25.89 | — |
| GHRS | GH Research PLC | $1.59B | $23.15 | — |
| QURE | uniQure N.V. | $1.59B | $25.15 | — |
| CMPS | COMPASS Pathways plc | $1.65B | $12.23 | — |
News headlines (Yahoo Finance, 1h cache)
Does AbCellera (ABCL) Have a Clear Path From ABCL635 Data to a Durable Business Model?
2026-05-24 14:13 · Yahoo
Here’s Why AbCellera (ABCL) is Among the 10 Best Penny Stocks to Buy for Long Term
2026-05-22 18:43 · Yahoo
Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade
2026-05-22 13:55 · Yahoo
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
2026-05-18 11:35 · Yahoo
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
2026-05-14 13:40 · Yahoo
Earnings Update: Here's Why Analysts Just Lifted Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$10.14
2026-05-14 12:58 · Yahoo
AbCellera Moves ABCL635 Into Phase 2 As Losses Continue
2026-05-13 00:27 · Yahoo
AbCellera Biologics Inc (ABCL) Q1 2026 Earnings Call Highlights: Promising Advancements Amid ...
2026-05-12 07:07 · Yahoo
AbCellera Biologics Q1 Earnings Call Highlights
2026-05-11 23:05 · Yahoo
AbCellera (ABCL) Q1 2026 Earnings Transcript
2026-05-11 22:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.